{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:46Z","timestamp":1787166166174,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00108-022-01291-2","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T09:12:51Z","timestamp":1647335571000},"page":"1000-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kausale Therapie der Alzheimer-Krankheit: Amyloidantik\u00f6rper","Causal treatment of Alzheimer\u02bcs disease: amyloid antibodies"],"prefix":"10.1007","volume":"63","author":[{"given":"Matthias","family":"Pawlowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Warnecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"1291_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"Alzheimer\u2019s Association","year":"2016","unstructured":"Alzheimer\u2019s Association (2016) 2016 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 12:459\u2013509","journal-title":"Alzheimers Dement"},{"key":"1291_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jama.2021.15286","volume":"326","author":"TS Anderson","year":"2021","unstructured":"Anderson\u00a0TS, Ayanian\u00a0JZ, Souza\u00a0J, Landon\u00a0BE (2021) Representativeness of participants eligible to be enrolled in clinical trials of Aducanumab for alzheimer disease compared with medicare beneficiaries with alzheimer disease and mild cognitive impairment. JAMA 326:1627\u20131629","journal-title":"JAMA"},{"key":"1291_CR3","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt\u00a0JW, Qian\u00a0F, Smith\u00a0BA et al (2018) Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid\u2011\u03b2. Sci Rep 8:6412","journal-title":"Sci Rep"},{"key":"1291_CR4","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1111\/ene.15007","volume":"28","author":"S Ayton","year":"2021","unstructured":"Ayton\u00a0S (2021) Brain volume loss due to donanemab. Eur J Neurol 28:e67\u2013e68","journal-title":"Eur J Neurol"},{"key":"1291_CR5","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3174\/ajnr.A3475","volume":"34","author":"F Barkhof","year":"2013","unstructured":"Barkhof\u00a0F, Daams\u00a0M, Scheltens\u00a0P et al (2013) An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR Am J Neuroradiol 34:1550\u20131555","journal-title":"AJNR Am J Neuroradiol"},{"key":"1291_CR6","first-page":"1","volume":"1","author":"TA Bayer","year":"2021","unstructured":"Bayer\u00a0TA (2021) Pyroglutamate A\u03b2 cascade as drug target in Alzheimer\u2019s disease. Mol Psychiatry 1:1\u20136","journal-title":"Mol Psychiatry"},{"key":"1291_CR7","first-page":"398","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings\u00a0J, Aisen\u00a0P, Apostolova\u00a0LG et\u00a0al (2021) Aducanumab: appropriate use recommendations. J\u00a0Prev Alzheimers Dis 8:398\u2013410","journal-title":"J Prev Alzheimers Dis"},{"key":"1291_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos\u00a0RB, Lu\u00a0J, Tang\u00a0Y et al (2012) A plaque-specific antibody clears existing \u03b2\u2011amyloid plaques in Alzheimer\u2019s disease mice. Neuron 76:908\u2013920","journal-title":"Neuron"},{"key":"1291_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan\u00a0MF, Kost\u00a0J, Voss\u00a0T et\u00a0al (2019) Randomized trial of verubecestat for prodromal alzheimer\u2019s disease. N\u00a0Engl J Med 380:1408\u20131420","journal-title":"N Engl J Med"},{"key":"1291_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","volume":"2","author":"J Ferrero","year":"2016","unstructured":"Ferrero\u00a0J, Williams\u00a0L, Stella\u00a0H et al (2016) First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement 2:169\u2013176","journal-title":"Alzheimers Dement"},{"key":"1291_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00115-021-01222-w","volume":"92","author":"L Fr\u00f6lich","year":"2021","unstructured":"Fr\u00f6lich\u00a0L, Hausner\u00a0L (2021) Disease-modifying treatment approaches for Alzheimer\u2019s disease. Nervenarzt 92:1239\u20131248","journal-title":"Nervenarzt"},{"key":"1291_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy\u00a0J, Allsop\u00a0D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 12:383\u2013388","journal-title":"Trends Pharmacol Sci"},{"issue":"80","key":"1291_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy\u00a0JA, Higgins\u00a0GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256(80):184\u2013185","journal-title":"Science"},{"key":"1291_CR14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert\u00a0LE, Weuve\u00a0J, Scherr\u00a0PA, Evans\u00a0DA (2013) Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census. Neurology 80:1778\u20131783. https:\/\/doi.org\/10.1212\/WNL.0b013e31828726f5","journal-title":"Neurology"},{"key":"1291_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.brainres.2007.09.048","volume":"1184","author":"S Higashi","year":"2007","unstructured":"Higashi\u00a0S, Iseki\u00a0E, Yamamoto\u00a0R et al (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer\u2019s disease and dementia with Lewy bodies. Brain Res 1184:284\u2013294","journal-title":"Brain Res"},{"key":"1291_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14283\/jpad.2020.68","volume":"8","author":"G Klein","year":"2021","unstructured":"Klein\u00a0G, Delmar\u00a0P, Kerchner\u00a0GA et al (2021) Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. J\u00a0Prev Alzheimers Dis 8:3\u20136. https:\/\/doi.org\/10.14283\/jpad.2020.68","journal-title":"J Prev Alzheimers Dis"},{"key":"1291_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein\u00a0G, Delmar\u00a0P, Voyle\u00a0N et al (2019) Gantenerumab reduces amyloid\u2011\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: A PET substudy interim analysis. Alzheimers Res Ther 11:1\u201312. https:\/\/doi.org\/10.1186\/s13195-019-0559-z","journal-title":"Alzheimers Res Ther"},{"key":"1291_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000486546","volume":"45","author":"R Knight","year":"2018","unstructured":"Knight\u00a0R, Khondoker\u00a0M, Magill\u00a0N et al (2018) A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord 45:131\u2013151","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1291_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston\u00a0G, Huntley\u00a0J, Sommerlad\u00a0A et\u00a0al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396:413\u2013446","journal-title":"Lancet"},{"key":"1291_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky\u00a0V, Satlin\u00a0A, Lai\u00a0R et\u00a0al (2016) Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer\u2019s disease with a\u00a0protofibril selective A\u03b2 antibody. Alzheimers Res Ther 8:14","journal-title":"Alzheimers Res Ther"},{"key":"1291_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun\u00a0MA, Lo\u00a0AC, Duggan Evans\u00a0C et\u00a0al (2021) Donanemab in early alzheimer\u2019s disease. N\u00a0Engl J Med 384:1691\u20131704","journal-title":"N Engl J Med"},{"key":"1291_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki\u00a0S, Lasser\u00a0RA, Dorflinger\u00a0E et\u00a0al (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther 9:95. https:\/\/doi.org\/10.1186\/s13195-017-0318-y","journal-title":"Alzheimers Res Ther"},{"key":"1291_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.25410","volume":"85","author":"F Panza","year":"2019","unstructured":"Panza\u00a0F, Lozupone\u00a0M, Seripa\u00a0D, Imbimbo\u00a0BP (2019) Amyloid\u2011\u03b2 immunotherapy for alzheimer disease: Is it now a\u00a0long shot? Ann Neurol 85:303\u2013315","journal-title":"Ann Neurol"},{"issue":"1","key":"1291_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway\u00a0S, Chalkias\u00a0S, Barkhof\u00a0F et\u00a0al (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early alzheimer disease. JAMA Neurol 2022;79(1):13\u201321","journal-title":"JAMA Neurol"},{"key":"1291_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway\u00a0S, Sperling\u00a0R, Fox\u00a0NC et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N\u00a0Engl J Med 370:322\u2013333. https:\/\/doi.org\/10.1056\/NEJMoa1304839","journal-title":"N Engl J Med"},{"key":"1291_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe\u00a0DJ (1991) The molecular pathology of Alzheimer\u2019s disease. Neuron 6:487\u2013498","journal-title":"Neuron"},{"key":"1291_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe\u00a0DJ, Hardy\u00a0J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol Med 8:595\u2013608","journal-title":"EMBO Mol Med"},{"key":"1291_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny\u00a0J, Chiao\u00a0P, Bussi\u00e8re\u00a0T et\u00a0al (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537:50\u201356","journal-title":"Nature"},{"key":"1291_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling\u00a0R, Salloway\u00a0S, Brooks\u00a0DJ et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a\u00a0retrospective analysis. Lancet Neurol 11:241\u2013249","journal-title":"Lancet Neurol"},{"key":"1291_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling\u00a0RA, Jack\u00a0CR, Black\u00a0SE et al (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement 7:367\u2013385","journal-title":"Alzheimers Dement"},{"key":"1291_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson\u00a0CJ, Zhang\u00a0Y, Dhadda\u00a0S et al (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther 13:80","journal-title":"Alzheimers Res Ther"},{"key":"1291_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrneurol.2012.135","volume":"8","author":"JD Warren","year":"2012","unstructured":"Warren\u00a0JD, Fletcher\u00a0PD, Golden\u00a0HL (2012) The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol 8:451\u2013464","journal-title":"Nat Rev Neurol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01291-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T06:03:12Z","timestamp":1661234592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01291-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01291-2","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"4 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Pawlowski und T.\u00a0Warnecke geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}